1 1

Roche

Actemra (Tocilizumab)

Actemra (Tocilizumab)

$0.00 USD
$0.00 USD
Sale Sold out
Shipping calculated at checkout.
Form & Size

Rheumatoid arthritis, Giant Cell Arteritis and Cytokine Release Syndrome. Actemra may be used alone or with other medications.Actemra belongs to a class of drugs called DMARDs, Immunomodulators; Monoclonal Antibodies.

In clinical trials of hospitalized patients with COVID-19, Actemra in addition to the routine care patients receive for treatment of COVID-19, which included corticosteroid therapy, was shown to reduce the risk of death through 28 days of follow-up and decrease the amount of time patients remained hospitalized
Indication
  • Rheumatoid arthritis

  • Giant Cell Arteritis (GCA)

  • Systemic Juvenile Idiopathic Arthritis (SJIA)

  • Polyarticular Juvenile Idiopathic Arthritis (PJIA)

  • Cytokine Release Syndrome (CRS)

The most common side effects of Actemra include:

  • runny or stuffy nose,
  • sinus pain,
  • sore throat,
  • headache,
  • increased blood pressure,
  • abnormal liver function tests, and
  • pain, swelling, burning, or irritation where the injection was given

 

General Considerations For Administration

   Avoid using ACTEMRA with biological DMARDs.

Storage and Stability

Do not use beyond expiration date on the container, package, prefilled syringe, or autoinjector. ACTEMRA must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect the vials, syringes, and autoinjectors from light by storage in the original package until time of use, and keep syringes and autoinjectors dry.

 

 

    Philippne FDA Info
    Registration Number BR-689
    Generic Name Tocilizumab
    Brand Name Actemra
    Dosage Strength 400mg / 20 mL
    Dosage Form Concentrate For Solution For I.V. Infusion
    Classification Prescription Drug (RX)
    Packaging 20 mL colorless Type I glass vial per box (box of 1's)
    Manufacturer Chugai Pharma Manufacturing Co., Limited
    Country of Origin Japan
    Trader F. Hoffmann-La Roche Limited - Switzerland
    Importer Roche (Philippines) Inc.
    Distributor Zuellig Pharma Corporation
    Issuance Date 18 June 2018
    Expiry Date 20 March 2023
    View full details